ArticleBlood advances2020

Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx.

Marcus A Carden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.